Comparison of albicans vs. non-albicans candidemia in French intensive care units

Critical Care

Volumn 14, Issue 3, 2010, Pages

  Leroy, Olivier ^a   Mira, Jean Paul ^b,c   Montravers, Philippe ^c,d   Gangneux, Jean Pierre ^e,f   Lortholary, Olivier ^c,g,h  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

^b Assistance publique ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE RENNES 1   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KLUYVEROMYCES MARXIANUS; MAJOR CLINICAL STUDY; NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; CLINICAL TRIAL; FEMALE; FRANCE; HOSPITALIZATION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

AGED; CANDIDA ALBICANS; CANDIDEMIA; FEMALE; FRANCE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77952737052     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9033     Document Type: Article

References (17)

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, . EPIC II Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319, EPIC II Group of Investigators.
2. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. 10.1128/AAC.49.9.3640-3645.2005, 1195428, 16127033.
3. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007, 60:613-618. 10.1093/jac/dkm212, 17576697.
4. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31. 10.1086/504810, 16758414.
5. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, . AmarCand Study Group Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618. 10.1097/CCM.0b013e31819efac0, 19325476, AmarCand Study Group.
6. Leroy O, Mira JP, Montravers P, Gangneux JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, . AmarCand Study Group [Invasive candidiasis in ICU: analysis of antifungal treatments in the French study AmarCand]. Ann Fr Anesth Reanim 2008, 27:999-1007. AmarCand Study Group.
7. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ, . Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, Mycoses Study Group of the National Institute of Allergy and Infectious Diseases Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14. 10.1086/323335, 11731939, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, Mycoses Study Group of the National Institute of Allergy and Infectious Diseases.
8. Clinical and laboratory standards institute. Antifungal susceptibility testing , http://www.clsi.org/source/orders/categories.cfm?section=Antifungal_Susceptibility_Testing&CAT=ANTIFUNGAL
9. Cheng MF, Yang YL, Yao TJ, Lin CY, Liu JS, Tang RB, Yu KW, Fan YH, Hsieh KS, Ho M, Lo HJ. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005, 5:22. 10.1186/1471-2334-5-22, 1090575, 15813977.
10. Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, Kollef MH. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007, 35:1077-1083. 10.1097/01.CCM.0000259379.97694.00, 17312565.
11. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703. 10.1086/599039, 19441981.
12. Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, Sorrell TC. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008, 36:2034-2039. 10.1097/CCM.0b013e3181760f42, 18552700.
13. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008, 46:1206-1213. 10.1086/529435, 18444857.
14. Holley A, Dulhunty J, Blot S, Lipman J, Lobo S, Dancer C, Rello J, Dimopoulos G. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009, 33:554. 10.1016/j.ijantimicag.2008.10.035, 19167196.
15. Société Française d'Anesthésie et de Réanimation Société de Pathologie Infectieuse de Langue Française Société de Réanimation de Langue Française Société Française d'Hématologie Société Française de Mycologie Médicale Société Française de Greffe de Mœlle (Consensus Conference) Management of invasive candidiasis and aspergillosis in adults. Rev Pneumol Clin 2004, 60:289-293. Société Française d'Anesthésie et de Réanimation Société de Pathologie Infectieuse de Langue Française Société de Réanimation de Langue Française Société Française d'Hématologie Société Française de Mycologie Médicale Société Française de Greffe de Mœlle (Consensus Conference).
16. Pappas PG, Kauffman CA, Andes D, Benjamin DK J, Calandra TF, Edwards JE J, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, . Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635, Infectious Diseases Society of America.
17. McCabe W, Jackson G. Gram-negative bacteremia: etiology and ecology. Arch Intern Med 1962, 110:847-855.